Targeting the transmembrane domain 5 of latent membrane protein 1 using small molecule modulators.

Protein-protein interactions (PPIs) play a critical role in living cells and represent promising targets for the drug discovery and life sciences communities. However, lateral transmembrane PPIs are difficult targets for small-molecule inhibitor development given less structural information is known and fewer ligand discovery methods have been explored compared to soluble proteins. In this study, the interactions of the transmembrane domain 5 (TMD-5) of latent membrane protein 1 (LMP-1) of Epstein-Barr virus (EBV) were disrupted by pentamidine derivatives to curb the committed step of EBV infection. A pentamidine derivative 2 with a 7-atom di-amide linker had the best activity whilst switching the amide regiochemistry in the linker influenced membrane permeability and abolished anti TMD-5 activity. Molecular dynamics simulations were performed to understand the interaction between pentamidine derivatives and TMD-5, and to rationalise the observed structure-activity relationships. This study explicitly demonstrated that the interaction of small molecule with lipid should be considered alongside interaction with the protein target when designing small molecules targeting the PPIs of TMDs. In all, this study provides proof of concept for the rational design of small molecules targeting transmembrane PPIs. Image 1 • Protein-protein interactions are vital in cells and represent promising target. • Protein-protein interfaces are difficult to target due to inherent challenges. • Compound 2 successfully targeted the interfaces and addressed this challenge. • The activity of compound 2 is extremely influenced by the regiochemistry of linker. • Interactions of molecule with lipid are vital when targeting the interfaces. [ABSTRACT FROM AUTHOR]